Fresenius Medical Care (FMS) Earns Daily Media Impact Score of 0.21

Press coverage about Fresenius Medical Care (NYSE:FMS) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fresenius Medical Care earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.1554607266612 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Fresenius Medical Care traded down $0.36, reaching $51.51, during trading hours on Friday, MarketBeat Ratings reports. 50,679 shares of the company’s stock were exchanged, compared to its average volume of 148,090. The company has a market cap of $31.79 billion, a PE ratio of 23.31, a PEG ratio of 2.81 and a beta of 0.62. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 0.53. Fresenius Medical Care has a fifty-two week low of $44.88 and a fifty-two week high of $57.94.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Thursday, May 3rd. The company reported $0.49 earnings per share for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.21). The company had revenue of $3.98 billion for the quarter, compared to analysts’ expectations of $4.07 billion. Fresenius Medical Care had a net margin of 7.29% and a return on equity of 11.09%. Fresenius Medical Care’s quarterly revenue was down 12.6% compared to the same quarter last year. During the same period last year, the firm earned $1.01 earnings per share. equities analysts forecast that Fresenius Medical Care will post 2.63 earnings per share for the current year.

The business also recently disclosed an annual dividend, which will be paid on Monday, June 4th. Stockholders of record on Tuesday, May 22nd will be issued a dividend of $0.436 per share. This represents a dividend yield of 0.86%. The ex-dividend date is Monday, May 21st.

A number of equities analysts recently commented on FMS shares. Deutsche Bank raised shares of Fresenius Medical Care from a “hold” rating to a “buy” rating in a research note on Tuesday, April 24th. DZ Bank reissued a “buy” rating on shares of Fresenius Medical Care in a research note on Monday, April 23rd. Zacks Investment Research raised shares of Fresenius Medical Care from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Thursday, March 8th. Finally, Royal Bank of Canada reissued a “neutral” rating on shares of Fresenius Medical Care in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $54.67.

About Fresenius Medical Care

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S.

Insider Buying and Selling by Quarter for Fresenius Medical Care (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply